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DMEM - 'XOEHFFR¶V0RGLILHG(DJOH¶V0HGLXP  
DMSO ± Dimethyl sulphoxide 
ECL ± Enhanced chemiluminescnece 
EDTA ± Ethylenediaminetetraacetic acid 
ELISA ± Enzyme-linked immunosorbent assay 
FBS ± Foetal bovine serum 
HDAC ± Histone deacetylase 
IFN-Ȗ± Interferon gamma 
IL-6 ± Interleukin 6 
LPS ± Lipopolysaccharide 
MAPK ± Microtubule associated protein kinase 
PBS ± Phosphate buffered saline 
qPCR ± Quantitative polymerase chain reaction 
SDS-PAGE ± Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
VPA ± Valproic acid 
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Abstract  
Histone deacetylase (HDAC) inhibitors prevent neural cell death in in vivo models of cerebral 
ischaemia, brain injury and neurodegenerative disease. One mechanism by which HDAC 
inhibitors may do this is by suppressing the excessive inflammatory response of chronically 
activated microglia. However, the molecular mechanisms underlying this anti-inflammatory 
effect and the specific HDAC responsible are not fully understood. Recent data from in vivo 
rodent studies has shown that inhibition of class I HDACs suppresses neuroinflammation and 
is neuroprotective. In our study we have identified that selective HDAC inhibition with 
inhibitors apicidin, MS-275 or MI-192, or specific knockdown of HDAC1 or 2 using siRNA, 
suppresses the expression of cytokines interleukin-6 (IL-6) and tumour necrosis factor-alpha 
(TNF-Din BV2 murine microglia activated with lipopolysaccharide (LPS). Furthermore, we 
found that in the absence of HDAC1, HDAC2 is upregulated and these increased levels are 
compensatory, suggesting these two HDACs have redundancy in regulating the inflammatory 
response of microglia. Investigating the possible underlying anti-inflammatory mechanisms 
suggests an increase in protein expression is not important. Taken together, this study supports 
the idea that inhibitors selective towards HDAC1 or HDAC2, may be therapeutically useful for 
targeting neuroinflammation in brain injuries and neurodegenerative disease.  
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INTRODUCTION  
 
Microglia are the innate immune cells of the brain that are responsible for the excessive and 
chronic neuroinflammatory response known to contribute to the pathogenesis of brain injury 
and disease (Block et al. 2007, Glass et al. 2010). Inhibitors of histone deacetylases (HDACs) 
reduce the inflammatory response of isolated microglia to stimulants such as 
lipopolysaccharide (LPS) (Kannan et al. 2013, Chen et al. 2007, Faraco et al. 2009, Peng et al. 
2005, Suh et al. 2010, Suuronen et al. 2003).  When delivered in vivo, HDAC inhibitors 
(HDACi) reduce neuroinflammation, promote neuroprotection and improve functional 
outcomes in models of cerebral ischaemia (Kim & Chuang 2014, Kim et al. 2007, Xuan et al. 
2012, Sinn et al. 2007), traumatic brain injury (Shein & Shohami 2011, Zhang et al. 2008) and 
encephalomyelitis (Camelo et al. 2005, Zhang et al. 2010). Therapies for treating brain injury 
and disease are lacking, but these studies highlight a role for HDACs in neuroinflammation 
and suggest they are appropriate targets to inhibit. 
 
The mechanism by which HDAC inhibition is anti-inflammatory is not understood, but we 
know HDACs remove acetyl groups from lysine residues on proteins including, histones 
(Strahl & Allis 2000), enzymes and transcription factors (Glozak et al. 2005, Yao & Yang 
2011). As a consequence, deacetylation of histones promotes a compact chromatin structure 
and reduces gene expression, and deacetylation of specific lysine residues on transcription 
factors can modulate their activity (Boyes et al. 1998, Gu & Roeder 1997) . 
 
The identity of which acetylated proteins are responsible for the anti-inflammatory responses 
observed when using HDAC inhibitors is unclear. There are 18 mammalian HDAC isoforms 
(class I HDACs (1, 2, 3 and 8), class II HDACs (4-7, 9 and 10), class III sirtuins (1-7) and the 
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class IV HDAC11) and the majority of studies to date have focused on using non-selective 
HDAC inhibitors such as suberoylanilide hydroxamic acid (SAHA), trichostatin-A (TSA) and 
valproic acid (VPA) which inhibit the majority of these isoforms. As a result, we do not know 
which HDACs modulate the microglial inflammatory response and how inhibition of these 
leads to the acetylation of specific proteins to reduce neuroinflammation. Recent studies have 
begun to address these questions and have shown that selective inhibition of Class I HDACs 1, 
2 and 3 with the HDAC inhibitor MS-275 (Hu et al. 2003, Simonini et al. 2006, Beckers et al. 
2007, Khan et al. 2008) FDQ UHGXFH QHXURLQIODPPDWLRQ LQ D PRXVH PRGHO RI $O]KHLPHU¶V
disease (Zhang & Schluesener 2013) and the inflammatory response of macrophages to the 
inflammatory stimulant LPS (Jeong et al. 2014).  
 
In our study, we have used selective HDAC inhibitors and siRNA knockdown to identify 
HDAC1 and HDAC2 as the key HDACs involved in the neuroinflammatory response of 
microglia. We show that selective class I HDAC inhibitors and siRNA to specifically knock-
down HDAC1 and 2, both suppressed the expression of cytokines in BV2 murine microglia. 
Knockdown of HDAC1 alone resulted in a compensatory increase in the levels of HDAC2 and 
did not suppress cytokine expression, showing these two enzymes have redundancy in the 
neuroinflammatory response. We show that the HDACi are effective in the absence of new 
protein synthesis suggesting that the mechanism of HDACi does not involve increased gene 
expression. This identification suggests that HDAC selective inhibitors may be therapeutically 
useful for targeting microglia and neuroinflammation, in brain injury and disease by 
modulating the acetylation levels and function of non-histone protein(s).  
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MATERIALS & METHODS 
 
CELL CULTURE  
 
BV-2 murine microglia (RRID:CVCL_0182, Interlab Cell Line Collection #ATL03001 (Blasi 
et al. 1990)) were cultured in 'XOEHFFR¶V0RGLILHG(DJOH¶V0HGLXPDMEM) high glucose 
AQmedia (Sigma-Aldrich) supplemented with 10% v/v foetal bovine serum (FBS, PAA Cell 
Culture Company) and 100U penicillin/100 Pg streptomycin (Sigma-Aldrich).  Cells were 
seeded into 6-well plates at either 350,000 or 500,000 cells/well and 24-well plates at 175,000 
cells/well. The cells were cultured 24 hours before treatment. BV-2 cells were treated with 
vehicle control, or HDAC inhibitor with or without 500 ng/mL lipopolysaccharide (LPS, 
Sigma), 1 ȝM oligomeric Beta-amyloid 1-42 (rPeptide) or 100 ng/ml Interferon gamma (IFN-
Ȗ and cells harvested after 6 or 24 hours. Inhibitors used were; Apicidin (Sigma-Aldrich), 
MI192 (University of Leeds), MS-275 (Cayman Chemicals), SAHA (Cayman Chemicals) all 
dissolved in DMSO and Valproic acid (VPA, Sigma-Aldrich) dissolved in PBS. For pre-
treatment experiments, BV-2 cells were treated with vehicle control or appropriate drugs for 
24 hours before addition of 500 ng/mL LPS for a further 6 hours. 
 
CELL TRANSFECTION 
 
BV2 microglia seeded into 6-well plates were washed with 1 mL PBS (Oxoid) and maintained 
in 1 mL Opti-MEM® (Gibco) throughout the transfection procedure. Cells were transfected 
with 50 pmoles of Silencer® Select Negative Control siRNA (Ambion) or Silencer® Select 
Pre-designed siRNA targeted against HDAC1 (id: s119557, Ambion) or HDAC2 (id: s67417, 
Ambion) as follows. For each well, 3 PL of Lipofectamine 2000 (Invitrogen) was dissolved 
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in 100 PL of Opti-MEM® and 1 PL of 50 PM siRNA was dissolved in 100 PL of Opti-Mem®, 
these were incubated for 5 minutes before combining and incubating for a further 20 minutes 
at room temperature. Afterwards, 200 PL of this mix was added to the well, followed by 
incubation at 37°C in a humid atmosphere with 5% CO2 for 4 hours. This was then removed 
and the cells were cultured in 3 mL DMEM high glucose AQmedia supplemented with 1% 
v/v FBS and 100U penicillin/100 Pg streptomycin for 24 hours followed by a medium change 
and culture for a further 24 hours before treating 500 ng/mL LPS for 6 hours. 
 
WHOLE CELL PROTEIN EXTRACTION 
 
BV2 cells seeded into 6-well plates were washed with 1 mL PBS and scraped into 250 PL ice-
cold RIPA Buffer [10 mM Tris-HCL pH 8.0, 1 mM EDTA, 1% Triton X-100, 0.1% sodium 
deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 140 mM NaCl, 1 mM PMSF (all from 
Sigma-Aldrich)], then incubated for 30 minutes on ice. The lysate was clarified by 
centrifugation at 13400 g for 20 minutes at 4°C and the supernatant containing proteins was 
collected and the concentration determined using the Bicinchoninic Acid (BCA) protein assay 
(Sigma-Aldrich). 
 
HISTONE PROTEIN EXTRACTION 
 
Histone proteins were extracted from BV2 microglia cultured in 6-well plates. Cells were 
washed with 1 mL PBS then scraped into 1 mL ice-cold PBS and pelleted by centrifugation at 
400 g for 5 minutes at room temperature. The cell pellet was resuspended in 400 PL of Triton 
Lysis Buffer per 1107 cells [0.5% v/v Triton X-100, 2 mM PMSF, 0.02% w/v NaN3 (all from 
Sigma-Aldrich)
 
and PBS] and incubated on ice for 10 minutes. Lysed cells were centrifuged at 
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6600 g for 10 minutes at 4°C. The pellet was resuspended in half the volume of Triton Lysis 
Buffer used earlier then centrifuged at 6600 g for 10 minutes at 4°C. The nuclei pellet was 
resuspended in 50 PL of 200 mM HCl (Acros Organics) and histone proteins were extracted 
overnight at 4°C. The samples were centrifuged at 6600 g for 10 minutes at 4°C and the 
supernatant containing histone proteins was collected and the protein concentration determined 
using the Bradford protein assay (Sigma-Aldrich). 
 
WESTERN BLOTTING 
 
Protein samples (10 Pg) were separated by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and wet-transferred onto PVDF membrane at 30V for 30 
minutes. The membranes were blocked overnight at 4°C with blocking solution [5% w/v nonfat 
dried milk powder, 0.1% v/v Tween® 20 (both from Sigma-Aldrich) and PBS] and then 
incubated with either; Anti-HDAC1 [1:2000, rabbit polyclonal, Abcam, RRID:AB_305705], 
Anti-HDAC2 [1:2000, rabbit polyclonal, Abcam, RRID:AB_305706], Anti-HDAC3 [1:2000, 
rabbit polyclonal, Abcam, RRID:AB_305708], Anti-E-actin [1:10,000, mouse monoclonal, 
Sigma, RRID:AB_476744], Anti-Histone H3 [1:1000, mouse monoclonal, Cell Signaling, 
RRID:AB_1642229], Anti-acetyl Histone H3 Lysine 9 [1:1000, rabbit polyclonal, Millipore, 
RRID:AB_310544] or Anti-acetyl Histone H4 Pan-lysine [1:10,000, rabbit polyclonal, 
Millipore, RRID:AB_310270] (all dissolved in blocking solution) for 1 hour at room 
temperature. Membranes were washed with PBS-0.1% v/v Tween® 20 and incubated with an 
appropriate secondary antibody; Goat-Anti-Rabbit IgG-horseradish peroxidase (HRP) linked 
[1:2000, Cell Signaling,  RRID:AB_2099233] or Goat-Anti-Mouse IgG-HRP linked [1:2000, 
Cell Signaling, RRID:AB_330924] for 1 hour at room temperature followed by washing as 
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(Amersham) and exposed to either photographic film, a Fujifilm LAS-3000 imaging system or 
a cDigit® Scanner (LICOR). The intensity of each band was quantified and normalized to the 
E-actin loading control. 
 
RNA EXTRACTION, REVERSE TRANSCRIPTION AND QUANTITATIVE PCR (qPCR) 
 
Total RNA was extracted from BV2 microglia cells using TRI Reagent® (Sigma-Aldrich) as per 
manufacWXUHU¶V instructions and resuspended in TE, pH 7.5 and concentration were determined 
using a NanoDrop 2000c (Thermo Scientific). RNA (2.5 Pg) was primed for reverse transcription 
at 65°C for 5 minutes with 1.25 PL of Oligo(dT)15 primers (0.5 Pg/PL, Promega), 1.25 PL of 
Random primers (0.5 Pg/PL, Promega) in a final volume of 32.5 PL. cDNA was synthesised at 
37oC for 60 min using M-MLV Reverse Transcriptase, RNase H Minus (200 U/PL and RNasin® 
Plus, Promega) with 2 mM dNTP (Bioline) in a final reaction volume of 50 PL. Quantitative 
PCR (qPCR) reactions were carried out in duplicate using a Rotor Gene 6000 PCR Analyzer 
(Corbett) using SensiMix SYBR® & Fluorescein (Bioline). Each reaction comprised of 50 or 
100 ng of sample cDNA, 300 nM of each gene primer, in a final volume of 20 PL. Primers used 
were: IL-¶-CCCAACTTCCAATGCTCTCC  DQG¶-ACATGGGATTCCACAAAC, TNF-
D¶-TGAACTTCGGGGTGATCG DQG¶-GGGCTTGTCACTCGAGTTTT 8¶- CCGCT-
TCGGCAGCACA  DQG ¶-AACGCTTCACGAATTTGCGT, HDAC1 ¶- GACCGCAAG-
TGTGTGG DQG¶-GAGCAACATTCCGGATGGTG, HDAC2 ¶- CAACAGATCGCGTGAT-
GACC DQG ¶-CCCTTTCCAGCACCAATATCC, +'$& ¶-GACGTGCATCGTGCTCC-
AGT DQG¶-ACATTCCCCATGTCCTCGAAT. An RNA control (no reverse transcription) and 
a no template control were also run. PCR conditions were: 95°C for 10 min followed by 45 cycles 
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of 95°C for 10 s, 60°C for 15 s and 72°C for 30 s. Relative quantitation of transcript levels was 
performed using the 2-''Ct method (Livak & Schmittgen, 2001) and the house-keeping gene U6.  
 
ENZYME LINKED IMMUNOSORBANT ASSAYS (ELISAs) 
 
Cell culture supernatants were taken from BV2 microglia cells cultured in 24-well plates. The 
culture medium was removed and centrifuged for 30 seconds at 16000 g to pellet any 
detached cells then 950 PL was removed for analysis. The concentration of mouse IL-6 protein 
was determined in triplicate by 96-well plate format ELISAs following Invitrogen¶V 
instructions.  
 
INHIBITION OF PROTEIN SYNTHESIS 
 
Cells were treated to 500 ng/mL LPS and either vehicle control, 1 µM SAHA or 500 
nM Apicidin, in the presence or absence of 1 µg/mL cycloheximide (CHX) for 3 hours. Protein 
synthesis was assessed in the cells using a Click-iT® Plus O-propargyl-puromycin (OPP) 
Protein Synthesis Assay Kit (Molecular Probes, Life Technologies). Briefly, after 2.5 hours of 
drug treatments, Click-iT® OPP was added directly to each well to give a final concentration 
of 20 µM. The cells were incubated for a further 30 minutes at 37°C. The culture medium was 
removed, the cells washed with PBS, followed by fixation with 100 µL of 4% w/v 
paraformaldehyde (Sigma-Aldrich) for 15 minutes at room temperature. The cells were then 
permeabilised with 100 µL of 0.5% v/v Triton X-100 (Sigma-Aldrich) for 15 minutes at room 
temperature, washed twice with PBS and processed for imaging IROORZLQJWKHPDQXIDFWXUHU¶V
LQVWUXFWLRQV,PDJLQJRIODEHOOHGFHOOVZDVFDUULHGRXWXVLQJWKH,QFX&\WH)/5ZLWKDî
objective lens. Nine non-overlapping images were taken in phase-contrast and green-
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fluorescence (excitation wavelength of 450-490 nm) per well. RNA was extracted from parallel 
treated cultures for qPCR analysis as described above. 
 
STATISTICS 
For qPCR experiments, data are presented either as mean percentage expression of the vehicle 
control ± SEM or mean percentage expression of LPS +vehicle condition ± SEM. Statistical 
analysis for each experimental condition vs. the vehicle condition was performed using a one-
way repeated measures ANOVA followed by the Dunnet post hoc test (Lew 2007) at the 5% 
significance level. For ELISA experiments, data is presented as mean protein concentration ± 
standard deviation (SD). Statistical analysis comparing the absolute absorbance values for each 
experimental condition vs. the vehicle control +LPS condition was performed using a 6WXGHQW¶V
unpaired t-test assuming equal variances at the 5% significance level. For all quantitative data 
experiments were performed in triplicate and each experiment was performed at least three times, 
WKH³n´ number represents number of experiments performed. No blinding was performed. 
 
RESULTS 
 
HDAC INHIBITION SUPPRESSES CYTOKINE EXPRESSION IN BV2 MICROGLIA 
 
Previous studies using isolated murine microglia report that non-selective HDAC inhibitors 
(SAHA, TSA and VPA) suppress LPS induced inflammation as measured by a reduction in 
LPS induced cytokine expression (tumour necrosis factor-alpha, TNF-D and interleukin-6, IL-
6) (Kannan et al. 2013, Suh et al. 2010). The specific HDAC(s) important in microglia and 
neuroinflammation are still largely unknown though identification of the specific HDAC is a 
requisite for the development of any targeted therapy. We first tested the response of LPS 
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activated BV2 microglia cells to the classical HDAC inhibitors SAHA and VPA. BV2 cells are 
a widely used model for primary microglia cells showing the same responses across a range of 
studies (Gresa-Arribas et al. 2012, Henn et al. 2009, Stansley et al. 2012, Horvath et al. 2008, 
Bocchini et al. 1992)). In response to LPS and IFN-Ȗ BV2 cells show the same elevation of 
TNF-D, IL-6, COX2, iNOS and NO as primary microglia (Gresa-Arribas et al. 2012). A 
transcriptomic analysis of the LPS response of primary microglia and BV2 cells showed that 
the gene induction involved the same genes, though the magnitude of change was higher in 
primary microglia (Henn et al. 2009). Like primary microglia, BV2 cells are capable of 
triggering astrocyte activation when co-cultured with them (Henn et al. 2009, Horvath et al. 
2008) phagoycytose AȕSHSWLGHV(He et al. 2011) and pre-stimulation with IL-10 prevents LPS 
induced cytokine expression (Gresa-Arribas et al. 2012). Thus BV2 cells show the same 
responses as primary microglia, providing a suitable model system to study mechanisms 
underlying these responses with the additional advantage that, unlike primary microglia 
cultures which are mixed cultures, BV2 cultures are homogenous. Six hours after stimulation 
with LPS, oligomeric Abeta or IFN-Ȗ,  IL-6 mRNA expression was increased (Fig 1A). 
Incubation of BV2 cells with the HDAC inhibitor SAHA, inhibited the stimulation of IL-6 
expression by each of the three stimulants used (Fig 1A). BV2 cells express the Class I HDACs, 
1, 2 and 3 with highest levels of HDAC1 and lowest levels of HDAC3 (Fig 1B, C). Treatment 
with the HDAC inhibitors, SAHA and VPA produced an increase in the level of Histone H4 
acetylation levels within 1hr which was stable over a period of 24 hr (Fig 1D) suggesting these 
inhibitors provide rapid and stable HDAC inhibition. Activation by LPS in the presence of 
either 1 PM SAHA or 5 mM of VPA, produced a significantly reduced response in IL-6 mRNA 
expression by 84.1 ± 2.8% (P = 0.004) and 89.7 ± 1.6%respectively and TNF-D mRNA 
expression by 59.7 ± 3.2%  and 77.9 ± 2.5%  respectively (Fig 1E). Furthermore, SAHA 
significantly suppressed the LPS induced increase in IL-6 protein secretion by 85.6 ± 2.5% 
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(Fig 1F). HDAC treatment did not have a significant effect on IL-6 levels in the absence of 
LPS stimulation (Fig 1A, E) and LPS treatment did not have a direct impact on HDAC mRNA 
levels (Fig 1G) or protein levels (Fig 1H) which remained unchanged. 
 
In order to understand the role of specific HDACs in microglia and neuroinflammation, we 
tested HDAC inhibitors that show some selectivity towards specific HDAC isoforms in vitro.  
We treated LPS induced cells with MS-275 (which has reported selectivity for HDAC1 
(Bradner, 2008)), 500 nM apicidin, or 1µM MI-192, (both of which have reported selectivity 
for HDAC2 and 3 (Khan, et al 2008; Boissinot et al., 2012)). Treatment of BV2 cells with these 
inhibitors showed a rapid and stable increase in acetylated Histone H4 for apicidin but a gradual 
increase for MS-275 and MI-192 over a 24 hour period (Fig 2A). Quantification of histone 
acetylation levels showed that apicidin produced a similar rate of increase to SAHA while MS-
275 and MI-192 required longer incubation periods to induce high levels of histone acetylation 
(Fig 2B). MS-275 and MI-192 are members of the benzamide class of HDAC inhibitors which 
have previously been shown to bind HDACs with a slower association rate compared to 
hydroxamic acid inhibitors such as SAHA (Lauffer et al. 2013). Consistent with these data, co-
treatment of LPS with apicidin was sufficient to reduce the induction of IL-6 and TNF-Į 
expression by 82.7 ± 2.3% and 50.3 ± 4.5% but co-treatment of MS-275 or MI-192 was not, 
(not shown). Pre-treatment of BV2 cells, to mitigate the slow kinetics of inhibition, with either 
apicidin, MI-912 or MS-275 for 24 hr prior to LPS stimulation significantly reduced the LPS 
stimulated expression of IL-6 and TNF-D (Fig 2C). Together these data suggest that HDAC1 
and HDAC2/3 contribute to the inflammatory response in microglia. 
   
KNOCKDOWN OF HDAC1 OR HDAC2 SUPRRESSES CYTOKINE EXPRESSION IN 
BV2 MICROGLIA 
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Although the HDAC inhibitors show selectivity, they are not isoform specific, therefore we 
used an siRNA approach to specifically knockdown HDAC1 and HDAC2 expression to 
determine their involvement in the inflammatory response of microglia. We were able to 
significantly knock-down HDAC1 protein expression by 62.6 ± 4.5% (Fig 3A) and HDAC2 
protein expression by 68.8 ± 7.7% (Fig 3A). Knockdown of HDAC1 resulted in an increased 
expression of HDAC2 with no change in HDAC3 expression (Fig 3A) while knockdown of 
HDAC2 did not result in any change of expression in HDACs 1 or 3 (Fig 3A).   Following 
knock-down, we treated cells to 500 ng/mL LPS for 6 hours and assessed the expression of IL-
6 and TNF-Į mRNA. We found, that cells in which HDAC1 was knocked down, we did not 
observe any change in the response to LPS compared to control cells (not shown) but cells in 
which HDAC2 was knocked down showed a reduced induction of IL-6 (by 48.2 ± 13%) and 
TNF-D (by 22.0 ± 3.6%) expression in response to LPS (Fig 3B). To determine if the increase 
in HDAC2 expression, as a result of HDAC1 knockdown, was acting as a compensatory 
mechanism we used siRNA to HDAC1 to knockdown HDAC1 in combination with a titrated 
amount of HDAC2 siRNA to reduce HDAC2 to levels seen in control cells (Fig. 3, HDAC1 + 
2). Using this titrated level of HDAC2 siRNA we were able to reduce  HDAC1 levels by 63.5 
± 2.4%, while maintaining the HDAC2 levels seen in control cells (89.7 ± 6.2%, Fig 3A 
HDAC1 + 2). Expression of HDAC3 was not significantly altered (116 ± 5% of Scr siRNA). 
Cells in which HDAC1 levels are reduced and HDAC2 levels are unchanged resulted in a 
reduced response of of IL-6 and TNF- Į P51$ WR /36 RI 34.8 ± 3.0% and 35.7 ± 4.8% 
respectively (Fig 3B).  
In summary our data identify HDAC1 and 2 activities as important contributors to the 
neuroinflammatory response of microglia. HDAC1 and 2 may have the same or independent 
roles in activation though the observation  that they show redundancy in this function with 
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increased HDAC2 levels being compensatory for reduced HDAC1 suggests there must be at 
least some overlap.  
 
HDAC INHIBITION IS EFFECTIVE IN REDUCING THE INFLAMMATORY RESPONSE 
IN THE ABSENCE OF NEW PROTEIN SYNTHESIS 
The mechanism by which HDAC inhibitors exert their effects is often assumed to 
involve increase in gene expression brought about as a result of increased histone acetylation 
Incubation of BV2 cells with these HDAC inhibitors do result in increased histone acetylation 
(eg Fig 1D) and the association of increased acetylation with increased gene expression was 
first identified nearly 30 years ago (Hebbes et al. 1988). However recent proteomic data has 
identified in excess of 4000 proteins that are modified by acetylation (Choudhary et al. 2009, 
Liu et al. 2014, Lundby et al. 2012), a number comparable to targets of phosphorylation and 
suggests that acetylation is involved in many more processes than gene regulation alone. To 
test a requirement for changes in gene expression for the anti-inflammatory action of HDAC 
inhibition we blocked new protein synthesis using cycloheximide and tested the effectiveness 
of HDAC inhibitors to block IL-6 and TNF-ĮVWLPXODWLRQE\/36Incubation of BV2 cells with 
cycloheximde for 1 or 3 hours completely blocked new protein synthesis as measured by O-
propargyl-puromycin incorporation and protein synthesis was blocked under all conditions 
used to quantify gene expression levels (Fig 4A). Continued exposure to cycloheximide for 6 
hr led to cell death (not shown) though 3 hr is sufficient time to observe the induction of IL-6 
mRNA by LPS stimulation (Fig 4B, left bar) and cells were still healthy at this time point. The 
presence of cycloheximde did not affect the induction of IL-6 mRNA expression by LPS (Fig 
4B, compare left two bars) and did not prevent either SAHA or Apicidin inhibiting this 
response (Fig 4B, right two bars). Thus these data indicate that the mechanism by which HDAC 
inhibition reduces the inflammatory response in microglia is manifest within 3 hours and does 
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not require new protein synthesis. Together this suggests that increased gene expression 
resulting from enhanced histone acetylation is not important for ability of HDAC inhibitors to 
reduce microglia activation and future work should am to identify the important molecular 
targets.   
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DISCUSSION  
 
It has been previously shown that inhibitors of HDACs can reduce the inflammatory response 
in activated microglia (Chen & Greene 2004, Faraco et al. 2009, Kannan et al. 2013, Suh et al. 
2010)  and by supressing microglia activation show neuroprotective effects following transient 
ischaemia in vivo (Kim & Chuang 2014, Kim et al. 2007, Sinn et al. 2007, Xuan et al. 2012). 
However, the identity of the important HDACs involved has not been uncovered and the 
mechanism by which HDAC inhibition is beneficial is yet to be elucidated. Here we have 
shown that the function of both HDAC1 and HDAC2 contribute to the inflammatory response 
in microglia and that in the absence of HDAC1, increased HDAC2 levels compensate 
suggesting that these 2 HDACs show redundancy in this function. Furthermore the 
effectiveness of HDAC inhibition in the absence of new protein synthesis suggests that the 
HDACs are promoting the inflammatory response by regulating the acetylation levels of a non-
histone protein rather than increasing levels of gene expression as a result of increased histone 
acetylation.  
 
Microglia are often referred to as the immune cells of the brain and recently, selective inhibition 
and genetic knock-down of class I HDACs, was shown to reduce the production of cytokines 
in the inflammatory response of macrophages (Jeong et al. 2014). In macrophages, knockdown 
of either HDAC1 or 2 resulted in increased expression of the other and only a combined 
knockdown of HDACs1, 2 and 3 resulted in reduced inflammatory response to LPS (Jeong et 
al. 2014). In T lymphocytes deletion of HDAC1 resulted in an increase in HDAC2 protein 
levels but deletion of HDAC2 had no effect on HDAC1 (Dovey et al. 2013). Here we show 
that in microglial cells, that HDAC1 is the most highly expressed class I HDAC and  
knockdown of HDAC1 resulted in a compensatory increase in the levels of HDAC2 (Fig 3A). 
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likewise, we did not observe any compensatory increase in the levels of HDAC1 protein upon 
knockdown of HDAC2 (Fig 3A) however this contrasts to observations made using 
macrophages (Jeong et al. 2014). The mechanisms resulting in a compensatory increase in one 
HDAC upon loss of another are not known though HDAC1 does regulate its own promoter 
(Schuettengruber et al. 2003) and may also repress expression of other HDACs. One prediction 
of such a model would be that chemical inhibition of HDAC activity would also result in such 
compensatory increase. However, we did not observe any compensatory changes in HDAC 
expression in cells treated with HDAC inhibitors (not shown), suggesting it is not brought about 
by loss of HDAC enzyme activity but is potentially a mechanism involving the absence of the 
protein itself. In the absence of HDAC1 in T-lymophocytes the levels of SIN3 and MTA2 are 
reduced which may indicate that incomplete co-repressor complexes are turned over quickly 
(Dovey et al. 2013). This structural, rather than enzymatic, requirement for HDAC1 may 
underlie the reason that knockdown of HDAC1, but not inhibition results in a compensatory 
increase in HDAC2. Additionally, compensatory changes in HDAC protein levels have been 
observed in the absence of changes in mRNA levels, suggesting the mechanism involves 
ebhanced translation or protein stability (Jurkin et al. 2011).  
 
HDAC1 and 2 do not exist in the cell as isolated enzymes but are components of 3 independent 
co-repressor complexes; Sin3, NuRD and CoREST (for a review see (Kelly & Cowley 2013)). 
Each co-repressor complex contains 2 molecules of HDAC which may consist of two 
molecules of HDAC1, two molecules of HDAC2 or one of each. Others have observed that 
upon a loss of HDAC1, HDAC2 can become incorporated into the Sin3, NuRD and CoREST 
multi-protein complexes in its place (Dovey et al. 2013). The compensatory effect of HDAC2 
in the inflammatory response may be explained by such a mechanism. Following a loss of 
HDAC1, HDAC2 is upregulated and this HDAC is incorporated into a specific complex in 
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place of HDAC1. This complex, specifically targets a protein, (which regulates the 
inflammatory response) for deacetylation. Regardless of the HDAC composition, be it two 
molecules of HDAC1, HDAC2 or one of each, the specificity for the substrate to be 
deacetylated comes from the complex itself rather than the HDACs. This hypothesis would 
VXJJHVWLWGRHVQ¶WPDWWHUZKLFKRIWKHWZR+'$&LVRIRUPVLVLQKLELted, an anti-inflammatory 
effect depends on a reduction in the number and activity of this specific functional multi-
protein complex. Similarly, the compensatory effect of HDAC3 when HDAC1 and 2 are both 
lost in macrophages (Jeong et al. 2014) may be explained by HDAC3 being in a specific 
complex that targets the same substrate as the complex with either HDAC1 or 2. Further 
research is now needed to investigate these hypotheses and identify the complexes (and 
composition of them) that when inhibited is responsible for the suppression of pro-
inflammatory mediator expression in BV2 microglia.  
 
What is the important target of HDAC1 and 2 that promotes the inflammatory response? 
HDAC enzymes were originally characterised by their ability to deacetylate histone proteins, 
however these are not their only target and the acetylome may contain on the order of 4000 
proteins (Choudhary et al. 2009, Liu et al. 2014). Additionally, the original idea, that HDAC 
inhibition leads to increased histone acetylation and increased gene expression is likely too 
simplistic because as many genes are repressed as are activated upon HDAC inhibition by 
SAHA (Peart et al. 2005). The specific HDAC target(s) important for the microglial response 
has not been unequivocally identified though a number of potential target proteins can be 
implicated based on a correlation of their acetylation with microglial activation. Perhaps the 
most studied non-histone protein involved in the inflammatory response and regulated by 
acetylation is the transcription factor NF-țB (Greene & Chen 2004) .  Quiescent NF-ț% is 
restricted to the cytoplasm via its inhibitory binding partner Iț% but upon cell stimulation 
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becomes dissociated form IKB and moves into the nucleus where it activates target gene 
expression. Initially, it was proposed that deacetylation of NF- ț% enhanced its interaction with 
,ț% and removal from the nucleus  however NF- ț% can be acetylated at multiple sites and 
more recent data suggests that deacetylation at specific residues can result in activation of a 
subset of NF-ț% targets (Rothgiesser et al. 2010) thus inhibition of HDACs may enhance the 
level of acetylated NF-ț%UHGXFLQJLWVDFWLYLW\In support of this idea, Furumai et al , 2011 
showed that inhibition of HDACs in HeLa cells, with  TSA, caused a reduction in the 
recruitment of NF-ț%, and RNA polymerase II to the promoter of IL-8 and a reduction in its 
expression (Furumai et al. 2011). In macrophages HDAC1, 2 and 3 can deacetylate MKP-1 
(which is a member of the MAPK signalling pathway) regulating its phosphorylation and 
reducing its activity (Jeong et al. 2014). MKP-1 is a negative regulator of the inflammatory 
response not just in macrophages but also in microglia (Eljaschewitsch et al. 2006) making this 
another attractive candidate for the functional response observed here.  
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Figure 1. Histone deacetylase (HDAC) inhibition suppress activation of cytokine 
expression in murine microglia. A) BV2 microglia were stimulated with 500 ng/mL 
lipopolysaccharide (LPS), 1 ȝM oligomeric Beta-Amyloid 1-42 (Abeta), 100 ng/ml IFN-Ȗ 
or vehicle (Con) in the presence or absence of 1 ȝM SAHA and mRNA expression of 
interleukin-6 (IL-6) was determined using qPCR. Relative transcript levels were 
normalized to the U6 gene and expressed as a percentage of the expression in LPS treated 
cells. Shown are mean ± SEM, n=3. B) Quantitative RT-PCR of RNA extracted from BV2 
cells. Expression levels are shown as a percentage of the U6 gene. Shown are mean ± SEM, 
n=3 C) Western blot analysis of protein extracted from BV2 cells and analysed using anti-
HDAC1, HDAC2, HDAC3 and ȕ-actin. Representative blots are shown and positions of 
molecular weight markers are identified on the left. D) Histone proteins were extracted 
from control cells and cells treated with 1 PM SAHA or 10 mM VPA for 1, 2, 4, 6, or 24hr. 
Proteins underwent western blotting for acetylated histone H4 (Ac-H4) and total histone 
H3. Representative blots are shown. E) BV2 microglia were treated with vehicle or 500 
ng/mL LPS ± 1 mM SAHA or 5 mM valproic acid (VPA) for 6 hours and the mRNA 
expression of IL-6 and TNF-a was determined using qPCR, normalized to the U6 house-
keeping gene and expressed as a percentage of the expression in control cells treated LPS, 
shown are mean ± SEM, n=3. F) BV2 microglia were treated with 500 ng/mL LPS ± 1 
mM SAHA for 24 hours and the changes in IL-6 protein secretion was determined by 
ELISA. Shown are mean protein concentration ± SEM, n=3.). G) Quantitative RT-PCR 
of RNA extracted from vehicle and LPS treated BV2 cells. Shown are HDAC mRNA 
levels in LPS treated cells expressed as a percentage of the HDAC levels in control cells, 
mean ± SEM, n=3 H) Quantitative western blot analysis of proteins extracted from 
vehicle and LPS treated BV2 cells. Shown are HDAC protein levels in LPS treated cells 
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expressed as a percentage of the HDAC levels in control cells, mean ± SEM, n=3   *P < 
0.05, **P  < 0.01, ***P < 0.001.  
Figure 2. Selective Histone deacetylase (HDAC) inhibitors suppress activation of cytokine 
expression in murine microglia. A) Histone proteins were extracted from control cells and 
cells treated with 500nM mM Apicidin, 1PM MI-192 or 5PM MS-275 for 1, 2, 4, 6, or 24hr. 
Proteins underwent western blotting for acetylated histone H4 (Ac-H4) and total histone H3. 
Representative blots are shown. B) Quantification of acetylated histone H4 levels, normalised 
to Histone H3 and expressed relative to acetylation levels at 24hr. C) BV2 microglia were 
pretreated with HDACi for 24 hours and then stimulated with vehicle or 500 ng/mL 
lipopolysacchatide (LPS) for 6 hours. mRNA expression  of interleukin-6 (IL-6) and tumor 
necrosis factor-a (TNF-a) was determined using qPCR. Relative transcript levels were 
normalized to the U6 house-keeping gene and expressed as a percentage of the expression in 
control cells treated with vehicle. Shown are mean ± SEM, n=3. *P < 0.05, **P  < 0.01, ***P 
< 0.001 compared to LPS stimulated cells.  
Figure 3. HDAC1 and HDAC2 are involved in the inflammatory response in microglia.  
A) BV2 microglia were transfected with either scrambled (Scr) siRNA or HDAC1, HDAC2  
or HDACs1 and 2 siRNAs. Levels of HDAC1, 2 and 3 and Beta-actin were quantified by 
immunoblotting. Shown are a representative blots (left) and quantification of protein levels 
(right) expressed relative to levels in cells treated with Scrambled siRNA. Shown are mean ± 
SEM, n=3 *p<0.05 compared to scrambled siRNA. B) BV2 microglia transfected with Scr, 
HDAC1, HDAC2 or HDAC1 and 2 siRNAs were stimulated with LPS and changes in IL-6 
and TNF-Į mRNA expression was determined using qPCR. Relative transcript levels in each 
treatment were normalized to the U6 gene and expressed relative to the expression in the Scr 
siRNA +LPS. Shown are mean ± SEM, n=3. *P < 0.05 
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Figure 4: Protein synthesis is not required for HDAC inhibitor efficacy. A) BV2 microglia 
were treated for 1 or 3 hours with or without cycloheximide and incorporation of O-propargyl-
puromycin (green, New protein) identified new protein synthesis. Bottom shows phase contrast 
images, scale bar 50 mm. B) Expression of the IL-6 was measured by quantitative PCR in cells 
exposed to LPS and treated with vehicle, SAHA or apicidin in the presence of cycloheximide. 
Transcript levels for each treatment were normalised to U6 and data shown are mean mRNA 
expression levels expressed as a percentage of the expression in LPS +vehicle ± SEM, n=3, 
***P<0.001 vs. LPS +vehicle 
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